DOT1L is a therapeutic target for MLL-r leukemia: genome-wide hypermethylation of H3K79 is characteristic to the cancer 24 and DOT1L's catalytic activity is required for expression of MLL-target genes, such as HoxA9 and Meis1. This evidence concerns the gene HOXA9 and leukemia.